7.3 Temperature Control & Targeted Temperature Management (TTM)

Temperature Control & Targeted Temperature Management (TTM)

Quick Answer (2025 AHA): For adult patients who remain unresponsive to verbal commands after ROSC, maintain temperature control for at least 36 hours. Temperature control includes hypothermic temperature control (32–34°C) or normothermic/fever-prevention temperature control (36–37.5°C). Keep the chosen strategy consistent, suppress shivering, and rewarm slowly when leaving a hypothermic target.

Post-anoxic brain injury is the leading cause of death and long-term disability after successful resuscitation. Ischemia–reperfusion injury triggers excitotoxicity, calcium overload, oxidative stress, mitochondrial injury, and neuroinflammation. Temperature control—historically taught as Targeted Temperature Management (TTM) or therapeutic hypothermia—blunts these pathways, lowers cerebral metabolic demand, and prevents fever-related secondary injury.

Why the 2025 Guidelines Emphasize "Temperature Control"

The 2025 American Heart Association Guidelines for CPR and ECC update post–cardiac arrest temperature language to temperature control, recognizing that both controlled hypothermia and active fever prevention are valid neuroprotective strategies. The Highlights document states it is reasonable to maintain temperature control for at least 36 hours in adults who remain unresponsive to verbal commands after ROSC. That 36-hour figure is the shortest recommended total duration of temperature control, not an optional early stop after 24 hours.

Clinicians studying for ACLS still encounter the term TTM in courses and algorithms. Treat TTM as the operational label for implementing temperature control: select a strategy, monitor core temperature continuously, prevent shivering, and avoid uncontrolled fever.

Indications and Patient Selection

Initiate temperature control for an adult who achieves ROSC but remains comatose, defined as absence of a meaningful response to verbal commands. Apply this recommendation regardless of:

1. Initial rhythm (VF/pVT or asystole/PEA)
2. Arrest location (OHCA or IHCA)

Patients who awaken promptly and follow commands do not need induced hypothermia, but fever prevention remains essential. Relative contraindications include severe uncontrolled hemorrhage, profound baseline hypothermia already below safe induction ranges, or goals-of-care directives that prioritize comfort over intensive neuroprotective therapy.

Two Evidence-Based Temperature Strategies (2025)

Either approach is acceptable under 2025 guidance. The clinical mandate is consistency: once a target strategy is chosen, avoid large fluctuations and do not oscillate between deep hypothermia and uncontrolled fever. Large comparative trials showed that preventing fever with a carefully controlled near-normothermic strategy can produce neurological outcomes comparable to deeper hypothermia in many cohorts—provided temperature is actively managed rather than left to chance.

Duration: At Least 36 Hours

Maintain temperature control for at least 36 hours. Older teaching often cited a 24-hour cooling plateau; the 2025 Highlights update the shortest recommended duration to 36 hours of total temperature control. Plan staffing, sedation, and monitoring around that minimum window.

Accurate core temperature monitoring is mandatory (esophageal probe, bladder thermistor, or pulmonary artery catheter). Axillary, oral, tympanic, and temporal measurements are too inaccurate to guide therapy.

Cooling Modalities and Induction

• Intravascular cooling systems: Closed-loop central venous catheters with circulating coolant provide rapid induction and stable maintenance.
• Surface cooling devices: Hydrogel pads or water-circulating blankets linked to automated feedback controllers.
• Cold IV fluids for induction only: Ice-cold (4°C) crystalloid boluses (often ~30 mL/kg) can accelerate induction in EMS or ED settings, but should not be the sole long-term maintenance method and must be used cautiously in pulmonary edema or severe heart failure.

Shivering Control

Shivering increases heat production, oxygen consumption, and CO₂ generation, undoing neuroprotection. Use a tiered approach:

1. Sedation and analgesia (e.g., propofol or midazolam plus a short-acting opioid)
2. Anti-shivering adjuncts (magnesium, buspirone, acetaminophen, dexmedetomidine as locally protocolized)
3. Neuromuscular blockade if shivering persists despite the above

Continuous EEG or train-of-four monitoring is warranted when paralysis is used so unrecognized seizures are not masked.

Controlled Rewarming and Late Fever Prevention

When leaving a hypothermic target, rewarm slowly—commonly 0.25–0.5°C per hour—to reduce vasodilation, electrolyte shifts, and rebound cerebral edema. Stop or carefully adjust potassium infusions before rewarming to avoid hyperkalemic arrest. After the temperature-control window, continue active fever prevention; late fever remains associated with worse secondary neuronal injury.

Exam Trap

Do not answer that temperature control ends at 24 hours. For ACLS written items aligned to 2025 science, the correct shortest recommended duration of post-ROSC temperature control in unresponsive adults is at least 36 hours, using either 32–34°C hypothermia or 36–37.5°C fever-prevention control.